Title

Large-scale seroepidemiologic surveillance of COVID-19 - Cross-sectional study in Hyogo
prefecture of Japan in August, 2021

Authors

Zhenxiao Ren¹, Koichi Furukawa, MD¹, Mitsuhiro Nishimura, PhD¹, Yukiya Kurahashi, MD¹,
Silvia Sutandhio, MD¹, Lidya Handayani Tjan, MD¹, Kaito Aoki¹, Natsumi Hasegawa¹, Jun
Arii, DVM, PhD¹, Kenichi Uto², Keiji Matsui, PhD², Itsuko Sato², Jun Saegusa, MD, PhD²,
Nonoka Godai³, Kohei Takeshita, PhD⁴, Masaki Yamamoto, PhD^{3,4}, Tatsuya Nagashima, MD,
PhD⁵, Yasuko Mori, MD, PhD^{1*}

Affiliations

¹Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School
of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan.

²Department of Clinical Laboratory, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku,
Kobe, Hyogo 650-0017, Japan.

³Laboratory of Macromolecular Dynamics and X-ray Crystallography, Department of Life
Science, University of Hyogo, 3-2-1 Kouto, Kamigori-cho, Ako-gun, Hyogo 678-1297, Japan.

⁴Life Science Research Infrastructure Group, Advanced Photon Technology Division, RIKEN
SPring-8 Center, 1-1-1 Koto, Sayo-cho, Sayo-gun, Hyogo 679-5148 Japan.

⁵Hyogo Prefecture Health Promotion Association, 2-1-12 Arata-cho, Hyogo-ku, Kobe, Hyogo
652-0032, Japan.

* Corresponding author

E-mail: ymori@med.kobe-u.ac.jp (YM)

Abbreviations

COVID-19: Coronavirus disease 2019

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2

ECLIA: Electrochemiluminescence immunoassay

ELISA: Enzyme-linked immunosorbent assay

N: Nucleocapsid

S: Spike

PBS: phosphate buffered saline

COI: cut-off index

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

36 ABTS: 2,2' -azino-bis(3-ethylbenzothiazoline-6-sulfonic acid

37

Abstract

The situation of the COVID-19 pandemic in Japan is drastically changing in the 2nd year, 2021, due to the appearance of SARS-CoV-2 variants of concern and the roll-out of mass vaccination. In addition to PCR diagnosis, periodic seroepidemiologic surveillance is important to analyze the epidemic situation. In this study, we analyzed the rate of seropositivity for the SARS-CoV-2 N and S antigens in Hyogo prefecture, Japan in August 2021. Sera collected from people who received a health check-up in a clinic of the Hyogo Prefecture Health Promotion Association were subjected to analysis of reactivity to the SARS-CoV-2 N and S antigens by electrochemiluminescence immunoassay (ECLIA) and enzyme-linked immunosorbent assay (ELISA), respectively. For a total 1,000 sera, the positive rates to N and S antigens were 2.1% and 38.7%, respectively. The infectious rate estimated by serological analysis based on the presence of the anti-N antibody was 2.5-fold higher than the value reported based on PCR-based analysis, and it increased five-fold compared to the rate determined by our previous seroepidemiologic study in October, 2020. The anti-S positive rate was almost consistent with the vaccination rate in this area. The observed high anti-S antibody level in the seropositive population may indicate that the mass vaccination in Japan is being performed smoothly at this time point, although the infectious rate has also increased.

Introduction

The COVID-19 pandemic, which first emerged in December 2019, has undergone several turning points, introducing drastic changes in its progress. One of the most important factors is the appearance of the SARS-CoV-2 variants of concern (VOCs) replacing the original variant. In Japan, the Alpha variant (B.1.1.7) replaced the existing strain by around April, 2021; then, the Delta variant (B.1.617.2) began spreading rapidly throughout the country from July to August, 2021 (2,16,22). The other critical event has been the launch of anti-COVID-19 vaccines. Accelerated development of several vaccine platforms was based on the components of the original SARS-CoV-2 strain as the template, and these vaccines were shown to be

effective for reducing the COVID-19 outbreak (17, 20). Although the COVID-19 vaccine rollout in Japan was delayed compared to that in other countries such as Israel and United States (19), the Comirnaty (BNT162b2 mRNA, BioNTech-Pfizer, Mainz, Germany/New York, United States) vaccine (25) was first approved in Japan and administered to health-care workers starting in February 2021, and elderly persons aged ≥ 65 years old starting April 2021, expanding to other populations from May, 2021. The mRNA vaccines developed by Moderna (7) were also approved and have been widely used in Japan from May 2021. The number of vaccinated people is increasing rapidly in Japan, as monitored by the government system (1). On September 13th, the government announced that 50.9% of the population in Japan has completed vaccination (<https://covid19.who.int/region/wpro/country/jp>). These two factors, that is, propagation of SARS-CoV-2 VOCs and the progress of the vaccination, may balance each other out, making predictions of the COVID-19 situation more difficult.

In October 2020, we conducted seroepidemiologic surveillance in Hyogo prefecture, population 5.5 million, located in the southern-central region of Japan, the so-called Kansai area (11). In our 1st seroepidemiologic surveillance, we reported that 0.15% of 10,377 sera had neutralizing activity against SARS-CoV-2 infection *in vitro*. The value 0.15% was interpreted to be the true infectious rate, and it was three times higher than the value (0.05%) estimated based on the PCR diagnosis at that time point (33), probably because the serological analysis could also detect persons with histories of asymptomatic infection.

In previous COVID-19 seroepidemiologic analyses, both the Nucleocapsid (N) and Spike (S) antigens of the SARS-CoV-2 were used as markers of infection; reactivity of serum antibodies against one or two of these antigens was detected (9, 21, 27, 33). However, currently the anti-N antibody is the major marker because the vaccines used in Japan protect individuals by inducing anti-S immunities including anti S-antibodies, making it is impossible to distinguish the S antibodies due to SARS-CoV-2 infection from those induced by vaccination. Nevertheless, analysis of the anti-S antibodies is of great importance because they are the key immune components for counteracting SARS-CoV-2 infection, and can serve as a marker of an

individual's potential to be protected from the infection (29, 31).

Under the current situation where infected and vaccinated people are both prevalent in society, seroepidemiologic surveillance can be used to accurately measure the proportion of individuals who have acquired SARS-CoV-2-specific antibodies by infection, vaccination or both. Seroepidemiologic surveillance is frequently conducted to understand and predict epidemics (8, 23, 26, 28, 35).

In this study, we reported the 2nd seroepidemiologic survey of COVID-19 in Hyogo prefecture from July to August 2021, which overlaps with the period of the 2020 Tokyo Olympics, delayed one year and held in Japan in the summer of 2021 (30). The anti-N antibody positivity rate revealed that the estimated infection rate was slightly higher than that reported by PCR diagnosis, whereas the anti-S antibody positive rate was consistent with the current vaccination rate in Hyogo prefecture. This report will be a milestone in the era during which the vaccine and SARS-CoV-2 VOCs are struggling for dominance.

Materials and methods

Samples

Serum samples were collected from people receiving health check-ups at the clinics of Hyogo Prefecture Health Promotion Association, Kobe, Japan from 19th July to 6th August. This retrospective observational study was explained on the website of Kobe University Hospital along with the opportunity to opt-out. Each serum was heat-treated at 56°C for 30 min and stored in 4°C until use.

Detection of anti-N antibody by electrochemiluminescence immunoassay (ECLIA)

An electrochemiluminescence immunoassay (ECLIA) was conducted using the cobas e801 module (Roche Diagnostics, Rotkreuz, Switzerland) as in our previous study (11). The Elecsys Anti-SARS-CoV-2 assay kit (Roche Diagnostics, Rotkreuz, Switzerland) is based on a double-antigen sandwich assay, which detects antibodies against the SARS-CoV-2 nucleocapsid

(N). The measurement was performed according to the manufacturer's instructions, and samples with a cut-off index (COI) > 1.0 were diagnosed as positive.

Expression and purification of SARS-CoV-2 spike protein

The Spike protein used for the ELISA assay was prepared by a recombinant expression system similar to that previously reported by another research group (15). Briefly, the gene sequence of the SARS-CoV-2 Spike ectodomain (amino acids 1-1213) was subcloned into a pCAGGS vector (24) with a puromycin-resistant gene. The Spike sequence used here includes following mutations: D614G, R682del, R683del, R685del, F817P, A892P, A899P, A942P, K986P, and V987P, and additional sequences: namely, an HRV-3c recognition site, T4 foldon, and a His-tag at the C-terminal side. The sequence was confirmed by the capillary electrophoresis sequencer DS3000 (Hitachi High-Tech).

Spike protein was expressed using the Expi293 expression system (ThermoFisher Scientific) according to the manufacturer's instruction. The culture supernatant was collected at four days post transfection. The His-tagged Spike protein was purified by Ni-NTA agarose (Qiagen) and size exclusion chromatography using the Superose 6 increase column and AKTA pure system (Cytiva).

Detection of anti-Spike antibodies by enzyme-linked immunosorbent assay (ELISA)

Anti-Spike antibodies in the human sera were detected by an enzyme-linked immunosorbent assay with the purified Spike ectodomain described above. Each well of the 96-well ELISA plate (Corning) was coated with 100 ng of purified Spike protein dissolved in a carbonate buffer at 4°C overnight. After washing the plate with PBS containing 0.1% Tween 20 (PBST) to remove the antigen, PBST supplemented with 1% bovine serum albumin was added as a blocking buffer followed by incubation at 4°C for 2 hours. Individual sera samples serially diluted from 1:40 to 1:5120 in the blocking buffer were added to the antigen-coated plate, and then incubated at 37°C for 1 hour. After washing with PBST, a goat anti-human IgG with

conjugated horseradish peroxidase (abcam) diluted 1:10000 with PBST was added as a secondary antibody followed by incubation at 37°C for 1 hour. After washing with PBST, 100 µl per well of ABTS solution (Roche) was added as substrate, and the plate was incubated at room temperature for 40 minutes in the dark. The reaction was stopped by adding 100 µl of 1.5% (w/v) oxalic acid dehydrate solution. The optical density at wavelength 405 nm (OD₄₀₅) was measured using the plate reader Multiskan FC (Thermofisher Scientific). Based on a preliminary experiment using sera from healthy volunteers (average 0.14; standard deviation: 0.022, n=12), we set a cut-off value of 0.3 for the 1:40 dilution to define positivity, with the aim of avoiding false positive detection. The value of the area under the curve (AUC) was used to evaluate the anti-S antibody amount (6, 12). The AUCs were calculated for the plot of OD₄₀₅ values according to dilution factors, and an arbitrary value of 1 was given as the width for a two-fold dilution step.

Ethics statement

This study was approved by the ethical committees of Kobe University Graduate School of Medicine (approval codes: B2156702). Hyogo Prefecture Health Promotion Association was also granted approval under the ethical committee of Kobe University Graduate School of Medicine. Information about this retrospective observational study was published on the website of Kobe University Hospital, along with the opportunity to opt out. To validate the ELISA, sera from COVID-19 patients and healthy volunteers were used under approval of the ethical committee of Kobe University Graduate School of Medicine (approval code B200200), and written informed consent was obtained from the donors.

Results

Summary of the samples

We collected sera from 1,000 persons who received a health check-up at a clinic of the Hyogo Prefecture Health Promotion Association in Hyogo prefecture. A summary of the

samples is shown in Table 1. The gender ratio was nearly equal: males, 58.7%; females, 41.3%. The age distribution was widely spread with a median of 48 (Table 1 and Figure 1A). The history of vaccination and infection were not included as selection or exclusion criteria; thus, no prior information was referred to in this study.

Reactivity of sera against the SARS-CoV-2 N and S antigens

The SARS-CoV-2 anti-N antibodies were detected by the electrochemiluminescence immunoassay (ECLIA) method (10, 11), and 21 of the 1,000 samples (2.1%) were deemed positive given the cut-off of 1.0 (Table 2). The age distribution of positive cases is shown in Figure 1B and Table 2. The positive rate for the age groups 30-39 yrs and 40-49 yrs were especially high, at 3.4% (6/179) and 4.1% (10/243), respectively. The positive rates for males and females were 2.7% (16/587) and 1.2% (5/413), respectively.

The anti-S antibodies were detected by the enzyme-linked immunosorbent assay (ELISA) method using a purified SARS-CoV-2 Spike protein. As a result, 38.7% (387/1,000) were positive given the cut-off of 0.3 (See the Materials and Methods). The age distribution of anti-S positive cases is shown in Figure 1C and Table 2. The positive rate for those in their 60s and 70s showed an apparently high rate, 70.7% (123/174) and 90.2% (37/41), respectively. On the other hand, the anti-S positive rates for younger age groups were relatively low; 18.9% (24/127), 31.3% (56/179), 27.6% (67/243), and 33.9% (80/236), for the age groups ≤ 29 y, 30-39 y, 40-49 y, and 50-59 y, respectively.

The correlation of measured scores for anti-N and anti-S antibodies was analyzed in N- positive cases and is shown in Figure 2. The Spearman's correlation factor was 0.42, indicating little correlation if any, probably due to the mixed effect of infection and vaccination for the value of the anti-S antibody. As expected, all the anti-N positive sera also were anti-S positive with one exception for a serum in which the N antibody detection value was also relatively low, probably due to a weak immune response

Distribution of anti-S antibody amount in sera

We further analyzed the distribution of the anti-S positive reactivity of the sera because it represents the amount of anti-S antibodies related to the neutralizing antibodies against SARS-CoV-2. The anti-S positive sera were further evaluated by serial dilution. Representative curves are shown in Figure 3A. The area under the curve (AUC), which indicates the amount of anti-S antibodies, was calculated for the 387 anti-S positive samples, and the distribution is plotted in Figure 3B. The median was 13.75, and the higher and lower quartile of the values were 17.45 and 8.79, respectively. In the same analysis, the AUC values for the serum of COVID-19 patient and that of a healthy control were 11.56 and 1.66, respectively. Thus, most of the anti-S-positive sera contained comparable amounts of anti-S antibodies to that of an actual COVID-19 patient. The anti-S AUC values for the anti-N positive sera were plotted in Figure 3C by extracting from the data of Figure 3B. The values are widely distributed within the range of whole AUC values, consistent with the result of Figure 2.

Discussion

Seroepidemiologic surveillance is a powerful approach to understanding the spread of infectious diseases in combination with other methods such as PCR diagnosis and antigen tests. Our surveillance in August 2021 revealed that the anti-N-positive rate, which represents the SARS-CoV-2 infectious rate, was 2.1%. At the end of the surveillance, the reported infectious rate based on PCR diagnosis was 0.85% and 0.80% in the Hyogo prefecture and in Japan, respectively (33), indicating approximately a 2.5-fold difference compared with the result in this study. The difference is accounted for by the existence of asymptotically or mildly infected individuals whose cases may not have been detected because they never underwent testing and PCR analysis. Indeed, a substantial portion of SARS-CoV-2 infected individuals are asymptomatic (4), leading to the inaccuracy of surveillance rates determined solely on PCR diagnosis. Although it is difficult to extrapolate our data directly to the whole population, they suggest that the infection is more widespread in Japan than the current PCR test results suggest

and indicate a need for more systematic testing. Nonetheless, the difference between the seroepidemiologic analysis and the PCR diagnosis was not overly large; i.e., the two sets of data are mutually validating.

The infectious rate of 2.1% revealed in this study in August 2021 is 14-fold higher than the rate 0.15% we reported in our 1st seroepidemiologic analysis in October 2020 (11). The infectious rate of the 1st surveillance was based on the neutralizing antibody titer; however, vaccination has made it difficult to analyze the relationship between the infection and the neutralizing antibody titer of the sera. In contrast to the anti-S antibody, the anti-N antibody is expected to be induced only by the SARS-CoV-2 infection as long as only S-targeted vaccines are used (13, 32). The anti-N analysis by the ECLIA method of the 1st surveillance for samples collected at the same clinic of the Hyogo Prefecture Health Promotion Association was 0.4% (4/1,000) (11), indicating a 5-fold increase at the same area in these 10 months. This result was not surprising considering the fact that after the 1st surveillance in October 2020, Japan including Hyogo prefecture experienced two additional waves of COVID-19 infection around January 2021 and May 2021; currently, we face the so-called fifth wave, which started in July, 2021 (3, 33).

As of August, 2021 vaccination in Japan with mRNA vaccines that induce anti-S-based immunity has been proceeding. As reported by our previous research and others, the vaccination actually induces neutralizing antibody in sera (14, 34), (Furukawa et al., manuscript submitted). According to the Japanese government system, the vaccination rate in the Hyogo prefecture as of August 6th, 2021 was 32.79% and 42.05% for single- or two-dose vaccinations, respectively (1). The revealed anti-S positive rate was 38.7% in this study; this result well represents the current progress in vaccination in Hyogo prefecture, Japan.

The observed high anti-S positive rate for the age groups 60-69 yrs and ≥ 70 yrs is explained by the priority vaccination for elderly people (more than 65 years old) in Japan (Figure 1C). The high anti-S positive rate might be related to the relatively low infection rate in these age groups (Figure 1B). However, the data for the age groups 50-59 yrs and < 29 yrsr, for

which both the anti-S and anti-N positive rates were relatively low, indicated that the low infectious rate could not be simply explained by the high anti-S positive rate of the age group. To understand the relatively high infectious rate for the age groups 30-39 yrs and 40-49 yrs shown in our data (Figure 1B), social reasons such as work commitments and social activities may need to be taken into consideration.

The relationship between the anti-S positive and the anti-N positive rate has become unclear because of the effect of vaccination. Actually, we could not find a correlation between the anti-N and the anti-S scores (Figure 2). Although all anti-N-positive sera were also positive for the anti-S antibody, with one exception, some of the sera showed high anti-S values with relatively low anti-N scores (Figure 2). Breakthrough infection for vaccinees may induce anti-N antibodies; however, the titers of the antibodies may be expected to be decreased owing to the prophylactic immunity induced by vaccination, preventing infection and viral replication. Actually, Allen et al. has reported that anti-N antibodies were hardly detected by the ECLIA methods we used in this study in cases of breakthrough infection (5). The cut-off value for the anti-N assays should be reconsidered in future seroepidemiologic studies in light of the high vaccination rate that is expected soon in Japan.

The COVID-19 situations in Japan and all over the world are rapidly changing day by day. This study was conducted during the build-up of social immunity by vaccination and the rapid spread of the SARS-CoV-2 Delta strain in Japan. It will become an important reference for future studies including our third epidemiological surveillance, which we anticipate will show a drastically altered situation of COVID-19.

Conflict of interest

The authors declare no conflict of interest in this research.

Funding

This work was supported by Hyogo Prefectural Government.

Acknowledgement

We thank Kazuro Sugimura MD, PhD (Superintendent, Hyogo Prefectural Hospital Agency and Professor, Kobe University) for his full support to promote this study. We express our sincere gratitude for cooperation and participation of staffs of Hyogo Prefecture Health Promotion Association. We also thank researchers of Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine and Hyogo Prefectural Kakogawa Medical Center.

Figure legends

Figure 1

Age distribution of the samples and seropositive rate. (A) Age distribution of the volunteers who provided the sera. Subjects were divided into six age groups as follows: 29 years or less (≤ 29 years), 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70 years or more (≥ 70 yrs). The anti-N positive rate (B) and anti-S positive rate (C) were calculated by age groups. The bars were painted according to the genders. For the anti-N, the measurement was performed once for all, and confirmed by a repeating measurement for the anti-N positive samples and anti-N negative samples with relatively high values (>0.25). For anti-S, all the positive samples were measured twice, and samples for which consistent results were obtained were counted as positive.

Figure 2

Correlation between the observed scores of anti-N and anti-S analysis. For the anti-N analysis, the cut of index value (COI) recorded by the device was used. For the anti-S analysis, the observed OD₄₀₅ value of the ELISA was used.

Figure 3

Qualitative analysis of the anti-S antibody amount. (A) Three representative curves plotting the

observed OD₄₀₅ values along the serial serum dilution factors are shown. The serum from a COVID-19 patient and that from a healthy donor were used as positive and negative controls, respectively. The areas under the curve were calculated from the individual curves and used as a reference of the anti-S amount. The calculated AUCs for the curves shown in (A) were as follows: Sample 1, 20.35; Sample 2, 3.59; Sample 3, 7.87; patient serum, 11.56; and healthy control: 1.66. (B) The distribution of AUC values from the anti-S ELISA ELISA curves are shown as a violin plot. The thick horizontal line stands for the median, 13.75, and the thin horizontal lines indicated the lower and higher quartile values, 8.79 and 17.45, respectively. The values for the patient sera and sera of healthy controls are indicated as filled and open arrowheads, respectively. (C) Distribution of anti-S AUC values for the anti-N positive sera. The exceptional sample determined as anti-S negative is shown as an open circle, and has the lowest value, as expected.

322 Tables

323 Tables 1. Information of the sample numbers and the age distribution

	All	Sex	
		Male	Female
Sample number, n (%)	1,000 (100%)	587 (58.7%)	413 (41.3%)
Age, yrs, median, (range)	48 (19-83)	51 (20-83)	44 (19-78)
Numbers by age group, n			
≤29 years	127	41	86
30-39 years	179	97	82
40-49 years	243	134	109
50-59 years	236	153	83
60-69 years	174	133	41
≥70 years	41	29	12

324

325 **Tables 2. Numbers of anti-N and anti-S positive samples by age groups**

		Sex	
		Male (n=587)	Female (n=413)
SARS-CoV-2 anti-N antibody (ECLIA)			
Positive No. by age group, n			
≤29 years (n=127)	1	0	1
30-39 years (n=179)	6	5	1
40-49 years (n=243)	10	7	3
50-59 years (n=236)	3	3	0
60-69 years (n=174)	1	1	0
≥70 years (n=41)	0	0	0
Positive No. in all participants, n (%)	21 (2.1%)	16 (2.7%)	5 (1.2%)
SARS-CoV-2 anti-S antibody (ELISA)			
Positive No. by age group, n			
≤29 years (n=127)	24	4	20
30-39 years (n=179)	56	30	26
40-49 years (n=243)	67	28	39
50-59 years (n=236)	80	48	32
60-69 years (n=174)	123	92	31
≥70 years (n=41)	37	26	11
Positive No. in all participants, n (%)	387 (38.7%)	228 (38.8%)	159 (38.5%)

326

References

1. Government CIOs' portal, Japan. COVID-19 Vaccination in Japan.
<https://cio.go.jp/en/index.php>, https://cio.go.jp/c19vaccine_dashboard.
2. Ministry of Health, Labour and Welfare. https://www.mhlw.go.jp/stf/covid-19/open-data_english.html.
3. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. .
<https://covid19.who.int/region/wpro/country/jp>. Accessed 15 September, 2021).
4. **Alene, M., L. Yismaw, M. A. Assemie, D. B. Ketema, B. Mengist, B. Kassie, and T. Y. Birhan.** 2021. Magnitude of asymptomatic COVID-19 cases throughout the course of infection: A systematic review and meta-analysis. *PLoS One* 16:e0249090.
5. **Allen, N., M. Brady, A. I. Carrion Martin, L. Domegan, C. Walsh, L. Doherty, U. N. Riain, C. Bergin, C. Fleming, and N. Conlon.** 2021. Serological markers of SARS-CoV-2 infection; anti-nucleocapsid antibody positivity may not be the ideal marker of natural infection in vaccinated individuals. *J Infect.*
6. **Amanat, F., D. Stadlbauer, S. Strohmeier, T. H. O. Nguyen, V. Chromikova, M. McMahon, K. Jiang, G. A. Arunkumar, D. Jurczynszak, J. Polanco, M. Bermudez-**

345 Gonzalez, G. Kleiner, T. Aydillo, L. Miorin, D. S. Fierer, L. A. Lugo, E. M.
346 Kojic, J. Stoeve, S. T. H. Liu, C. Cunningham-Rundles, P. L. Felgner, T.
347 Moran, A. Garcia-Sastre, D. Caplivski, A. C. Cheng, K. Kedzierska, O.
348 Vapalahti, J. M. Hepojoki, V. Simon, and F. Krammer. 2020. A serological assay
349 to detect SARS-CoV-2 seroconversion in humans. *Nat Med* **26**:1033-1036.

350 7. Baden, L. R., H. M. El Sahly, B. Essink, K. Kotloff, S. Frey, R. Novak, D.
351 Diemert, S. A. Spector, N. Rouphael, C. B. Creech, J. McGettigan, S. Khetan, N.
352 Segall, J. Solis, A. Brosz, C. Fierro, H. Schwartz, K. Neuzil, L. Corey, P. Gilbert,
353 H. Janes, D. Follmann, M. Marovich, J. Mascola, L. Polakowski, J. Ledgerwood,
354 B. S. Graham, H. Bennett, R. Pajon, C. Knightly, B. Leav, W. Deng, H. Zhou, S.
355 Han, M. Ivarsson, J. Miller, and T. Zaks. 2021. Efficacy and Safety of the
356 mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* **384**:403-416.

357 8. Batool, H., O. Chughtai, M. D. Khan, A. S. Chughtai, S. Ashraf, and M. J. Khan.
358 2021. Seroprevalence of COVID-19 IgG antibodies among healthcare workers of
359 Pakistan: a cross-sectional study assessing exposure to COVID-19 and
360 identification of high-risk subgroups. *BMJ Open* **11**:e046276.

361 9. den Hartog, G., R. M. Schepp, M. Kuijer, C. GeurtsvanKessel, J. van Beek, N.
362 Rots, M. P. G. Koopmans, F. R. M. van der Klis, and R. S. van Binnendijk. 2020.

363 SARS-CoV-2-Specific Antibody Detection for Seroepidemiology: A Multiplex
364 Analysis Approach Accounting for Accurate Seroprevalence. J Infect Dis
365 222:1452-1461.

366 10. Egger, M., C. Bundschuh, K. Wiesinger, C. Gabriel, M. Clodi, T. Mueller, and
367 B. Dieplinger. 2020. Comparison of the Elecsys(R) Anti-SARS-CoV-2
368 immunoassay with the EDI enzyme linked immunosorbent assays for the
369 detection of SARS-CoV-2 antibodies in human plasma. Clin Chim Acta 509:18-
370 21.

371 11. Furukawa, K., J. Arie, M. Nishimura, L. H. Tjan, A. Lystia Poetranto, Z. Ren, S.
372 Aktar, J. R. Huang, S. Sutandhio, Y. Kurahashi, A. Nishino, S. Shigekuni, Y.
373 Takeda, K. Uto, K. Matsui, I. Sato, Y. Inui, K. Endo, Y. Kosaka, T. Oota, J.
374 Saegusa, and Y. Mori. 2021. Seroepidemiological Survey of the Antibody for
375 Severe Acute Respiratory Syndrome Coronavirus 2 with Neutralizing Activity at
376 Hospitals: A Cross-sectional Study in Hyogo Prefecture, Japan. JMA J 4:41-49.

377 12. Gaebler, C., Z. Wang, J. C. C. Lorenzi, F. Muecksch, S. Finkin, M. Tokuyama,
378 A. Cho, M. Jankovic, D. Schaefer-Babajew, T. Y. Oliveira, M. Cipolla, C. Viant,
379 C. O. Barnes, Y. Bram, G. Breton, T. Hagglof, P. Mendoza, A. Hurley, M.
380 Turroja, K. Gordon, K. G. Millard, V. Ramos, F. Schmidt, Y. Weisblum, D. Jha,

- 381 M. Tankelevich, G. Martinez-Delgado, J. Yee, R. Patel, J. Dizon, C. Unson-
382 O'Brien, I. Shimeliovich, D. F. Robbani, Z. Zhao, A. Gazumyan, R. E. Schwartz,
383 T. Hatzioannou, P. J. Bjorkman, S. Mehandru, P. D. Bieniasz, M. Caskey, and
384 M. C. Nussenzweig. 2021. Evolution of antibody immunity to SARS-CoV-2.
385 Nature **591**:639-644.
- 386 13. Harris, R. J., H. J. Whitaker, N. J. Andrews, F. Aiano, Z. Amin-Chowdhury, J.
387 Flood, R. Borrow, E. Linley, S. Ahmad, L. Stapley, B. Hallis, G. Amirthalingam,
388 K. Hoschler, B. Parker, A. Horsley, T. J. G. Brooks, K. E. Brown, M. E. Ramsay,
389 and S. N. Ladhani. 2021. Serological surveillance of SARS-CoV-2: Six-month
390 trends and antibody response in a cohort of public health workers. J Infect
391 **82**:162-169.
- 392 14. Hirotsu, Y., K. Amemiya, H. Sugiura, M. Shinohara, M. Takatori, H. Mochizuki,
393 and M. Omata. 2021. Robust Antibody Responses to the BNT162b2 mRNA
394 Vaccine Occur Within a Week After the First Dose in Previously Infected
395 Individuals and After the Second Dose in Uninfected Individuals. Front
396 Immunol **12**:722766.
- 397 15. Hsieh, C. L., J. A. Goldsmith, J. M. Schaub, A. M. DiVenere, H. C. Kuo, K.
398 Javanmardi, K. C. Le, D. Wrapp, A. G. Lee, Y. Liu, C. W. Chou, P. O. Byrne, C.

399 K. Hjorth, N. V. Johnson, J. Ludes-Meyers, A. W. Nguyen, J. Park, N. Wang, D.
400 Amengor, J. J. Lavinder, G. C. Ippolito, J. A. Maynard, I. J. Finkelstein, and J. S.
401 McLellan. 2020. Structure-based design of prefusion-stabilized SARS-CoV-2
402 spikes. *Science* **369**:1501-1505.

403 16. Ito, K., C. Piantham, and H. Nishiura. 2021. Predicted dominance of variant
404 Delta of SARS-CoV-2 before Tokyo Olympic Games, Japan, July 2021. *Euro*
405 *Surveill* **26**.

406 17. Izda, V., M. A. Jeffries, and A. H. Sawalha. 2021. COVID-19: A review of
407 therapeutic strategies and vaccine candidates. *Clin Immunol* **222**:108634.

408 18. Izumo, T., N. Kuse, N. Awano, M. Tone, K. Sakamoto, K. Takada, Y. Muto, K.
409 Fujimoto, A. Saiki, Y. Ito, H. Matsumoto, and M. Inomata. 2021. Side effects
410 and antibody titer transition of the BNT162b2 messenger ribonucleic acid
411 coronavirus disease 2019 vaccine in Japan. *Respir Investig* **59**:635-642.

412 19. Kosaka, M., T. Hashimoto, A. Ozaki, T. Tanimoto, and M. Kami. 2021. Delayed
413 COVID-19 vaccine roll-out in Japan. *Lancet* **397**:2334-2335.

414 20. Lopez Bernal, J., N. Andrews, C. Gower, C. Robertson, J. Stowe, E. Tessier, R.
415 Simmons, S. Cottrell, R. Roberts, M. O'Doherty, K. Brown, C. Cameron, D.
416 Stockton, J. McMenamin, and M. Ramsay. 2021. Effectiveness of the Pfizer-

- 417 BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms,
418 hospital admissions, and mortality in older adults in England: test negative case-
419 control study. *BMJ* **373**:n1088.
- 420 21. **Megasari, N. L. A., T. Utsumi, L. N. Yamani, Juniastuti, E. Gunawan, K.**
421 **Furukawa, M. Nishimura, M. I. Lusida, and Y. Mori.** 2021. Seroepidemiological
422 study of SARS-CoV-2 infection in East Java, Indonesia. *PLoS One* **16**:e0251234.
- 423 22. **Murayama, H., T. Kayano, and H. Nishiura.** 2021. Estimating COVID-19 cases
424 infected with the variant alpha (VOC 202012/01): an analysis of screening data
425 in Tokyo, January-March 2021. *Theor Biol Med Model* **18**:13.
- 426 23. **Naesens, R., H. Mertes, J. Clukers, S. Herzog, C. Brands, P. Vets, I. De Laet, P.**
427 **Bruynseels, P. De Schouwer, S. van der Maas, K. Bervoets, N. Hens, and P. Van**
428 **Damme.** 2021. SARS-CoV-2 seroprevalence survey among health care providers
429 in a Belgian public multiple-site hospital. *Epidemiol Infect* **149**:e172.
- 430 24. **Niwa, H., K. Yamamura, and J. Miyazaki.** 1991. Efficient selection for high-
431 expression transfectants with a novel eukaryotic vector. *Gene* **108**:193-9.
- 432 25. **Polack, F. P., S. J. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, J.**
433 **L. Perez, G. Perez Marc, E. D. Moreira, C. Zerbini, R. Bailey, K. A. Swanson, S.**
434 **Roychoudhury, K. Koury, P. Li, W. V. Kalina, D. Cooper, R. W. Frenck, Jr., L. L.**

- 435 Hammitt, O. Tureci, H. Nell, A. Schaefer, S. Unal, D. B. Tresnan, S. Mather, P.
436 R. Dormitzer, U. Sahin, K. U. Jansen, and W. C. Gruber. 2020. Safety and
437 Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med **383**:2603-
438 2615.
- 439 26. Santosh, C. S., D. P. Tukaram, K. Maharudra, A. Balkrishna, G. Chinmay, I.
440 Aniket, K. Kinge, and J. Nilam. 2021. Seroprevalence of SARS-CoV-2
441 Antibodies and Associated Factors in Health Care Workers. J Assoc Physicians
442 India **69**:11-12.
- 443 27. Selvaraju, S., M. S. Kumar, J. W. V. Thangaraj, T. Bhatnagar, V. Saravanakumar,
444 C. P. G. Kumar, K. Sekar, E. Ilayaperumal, R. Sabarinathan, M. Jagadeesan, M.
445 S. Hemalatha, and M. V. Murhekar. 2021. Population-Based Serosurvey for
446 Severe Acute Respiratory Syndrome Coronavirus 2 Transmission, Chennai,
447 India. Emerg Infect Dis **27**:586-589.
- 448 28. Smigelskas, K., K. Petrikonis, V. Kasiulevicius, R. Kalediene, A. Jakaitiene, S.
449 Kaseliene, S. Sauliune, A. Berzanskyte, and M. Stankunas. 2021. SARS-CoV-2
450 Seroprevalence in Lithuania: Results of National Population Survey. Acta Med
451 Litu **28**:48-58.
- 452 29. Steensels, D., N. Pierlet, J. Penders, D. Mesotten, and L. Heylen. 2021.

- 453 Comparison of SARS-CoV-2 Antibody Response Following Vaccination With
454 BNT162b2 and mRNA-1273. JAMA.
- 455 30. **Tokuda, Y., and T. Kuniya.** 2021. Prediction of COVID-19 cases during Tokyo's
456 Olympic and Paralympic Games. J Gen Fam Med **22**:171-172.
- 457 31. **Wang, Z., F. Schmidt, Y. Weisblum, F. Muecksch, C. O. Barnes, S. Finkin, D.**
458 **Schaefer-Babajew, M. Cipolla, C. Gaebler, J. A. Lieberman, T. Y. Oliveira, Z.**
459 **Yang, M. E. Abernathy, K. E. Huey-Tubman, A. Hurley, M. Turroja, K. A. West,**
460 **K. Gordon, K. G. Millard, V. Ramos, J. Da Silva, J. Xu, R. A. Colbert, R. Patel, J.**
461 **Dizon, C. Unson-O'Brien, I. Shimeliovich, A. Gazumyan, M. Caskey, P. J.**
462 **Bjorkman, R. Casellas, T. Hatziioannou, P. D. Bieniasz, and M. C. Nussenzweig.**
463 2021. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating
464 variants. Nature **592**:616-622.
- 465 32. **Whitaker, H. J., S. Elgohari, C. Rowe, A. D. Otter, T. Brooks, E. Linley, I.**
466 **Hayden, S. Ribeiro, J. Hewson, A. Lakhani, E. Clarke, C. Tsang, C. N. Campbell,**
467 **M. Ramsay, K. Brown, and G. Amirthalingam.** 2021. Impact of COVID-19
468 vaccination program on seroprevalence in blood donors in England, 2021. J
469 Infect **83**:237-279.
- 470 33. **Yazaki, S., T. Yoshida, Y. Kojima, S. Yagishita, H. Nakahama, K. Okinaka, H.**

471 **Matsushita, M. Shiotsuka, O. Kobayashi, S. Iwata, Y. Narita, A. Ohba, M.**
472 **Takahashi, S. Iwasa, K. Kobayashi, Y. Ohe, A. Hamada, T. Doi, and N.**
473 **Yamamoto.** 2021. Difference in SARS-CoV-2 Antibody Status Between Patients
474 With Cancer and Health Care Workers During the COVID-19 Pandemic in
475 Japan. JAMA Oncol **7**:1141-1148.

476 34. **Yoshimura, Y., H. Sasaki, N. Miyata, K. Miyazaki, and N. Tachikawa.** 2021.
477 Antibody response after COVID-19 vaccine BNT162b2 on health care workers
478 in Japan. J Infect Chemother.

479 35. **Zurcher, K., C. Mugglin, F. Suter-Riniker, P. M. Keller, M. Egger, S. Muller, M.**
480 **Fluri, M. Hoffmann, and L. Fenner.** 2021. Seroprevalence of SARS-CoV-2 in
481 healthcare workers from outpatient facilities and retirement or nursing homes in
482 a Swiss canton. Swiss Med Wkly **151**.

483
484

Figure 1

Figure 2

Figure 3